amantadine / Generic mfg. - LARVOL DELTA

Environmental occurrence of amantadine and rimantadine in aquaculture pond sediments: application of a newly developed LC-MS/MS method. (PubMed, Environ Monit Assess) - "The validated method provides a robust tool for routine environmental monitoring and contributes baseline data on the occurrence of AMT and RMT in aquaculture systems. Overall, this research underscores the need for stricter drug management policies, improved aquaculture practices, and further studies on the long-term environmental fate and risks of antiviral residues in aquatic ecosystems."

Journal

Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review. (PubMed, CNS Drugs) - "Current pharmacological interventions explored in disorders of consciousness target distinct molecular systems, including dopaminergic modulators (amantadine, levodopa, apomorphine, bromocriptine, selegiline, methylphenidate, and modafinil), GABAergic agents (zolpidem and baclofen), and other neuromodulatory compounds acting on glutamatergic, opioid, or serotonergic receptors (ketamine, remifentanil, and psilocin). Safety profiles associated with these treatments are also critically evaluated to guide clinical decision making. By integrating current knowledge on pharmacological modulation of key neural systems, including dopaminergic and GABAergic pathways, this article provides a comprehensive framework for understanding treatment strategies in disorders of consciousness."

Journal • Review

Diamonds for the Mind: Exploring the Potential of Adamantane against Alzheimer's Disease. (PubMed, Mini Rev Med Chem) - "Amino-substituted adamantanes, such as amantadine and memantine, display anti-Alzheimer potential due to improved NMDA receptor affinity and CNS permeability. Adamantane's physicochemical features make it a preferred framework for future CNS-targeted therapies. Given the increasing need for more effective AD treatments, adamantane-based compounds present a viable option for new drug development."

Journal • Alzheimer's Disease • CNS Disorders • Dementia

AMANTADINE FOR LEVODOPA INDUCED DYSKINESIAS IN PD: PREVALENCE, CLINICAL CORRELATES, AND TREATMENT OUTCOMES IN THE PPMI STUDY COHORT. (ADPD 2026) - "Amantadine use was reported for 29% of subjects with dyskinesia, a majority with lower than recommended doses. Approximately one third discontinued amantadine. MDS-UPDRS-4 (Complications of therapy) was independent of general PD-severity measures."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

DYNAMIC CHANGES IN THE MOTOR SPHERE AGAINST THE BACKGROUND OF THE USE OF AMANTADINE IN PATIENTS WITH MULTIPLE SCLEROSIS (ADPD 2026) - "Adding amantadine to the treatment regimen of patients with multiple sclerosis allows for improved motor activity by reducing muscle tone. Amantadine accelerates the recovery of motor functions, improves cognitive functions and quality of life in patients with multiple sclerosis."

Clinical • CNS Disorders • Multiple Sclerosis • Otorhinolaryngology

Therapeutic Use of Melatonin for Gastrointestinal Motility and Hypersomnolence in a Patient With Pineal Cyst Pathology. (PubMed, Am J Case Rep) - "Amantadine and sertraline were used in conjunction with melatonin. The report is limited by being a single case with lack of a control group, and use of concurrent medications. Larger, controlled studies are needed to further explore the mechanisms involved in the relationships between melatonin, GI functioning, and sleep dysregulation."

Journal • CNS Disorders • Mood Disorders • Psychiatry

Amantadine Enhances IL-10 Expressions to Maintain the Renal Functions Against Inflammation and Oxidative Stress via Increasing PI3K/AKT/HIF-1α Pathway and Decreasing AQP2-4 Signallings. (PubMed, Basic Clin Pharmacol Toxicol) - "In this study, AMA treatment exhibited anti-inflammatory effects on kidney tissue via several different mechanisms. However, additional studies with varied doses and durations of AMA treatment, involving different pathways and detailed analyses, are necessary."

Journal • CNS Disorders • Hematological Disorders • Inflammation • Movement Disorders • Parkinson's Disease • Renal Disease • HIF1A • IL10

Amantadine for levodopa induced dyskinesias in PD: Prevalence, clinical correlates, and treatment outcomes in the PPMI study cohort (ACCESS Newswire) - "Here, we examined use patterns of amantadine in a large observational PD-cohort. Clinimetric, demographic, genotype and imaging data on 1340 subjects with PD were accessed November- 2025....Amantadine was used by about 30% of subjects with dyskinesia, with roughly one-third eventually discontinuing as their disease progressed. Most patients received daily doses below 300 mg. Dyskinetic subjects on amantadine tended to have more severe PD symptoms across modalities, including overall severity, ADL-function, cognitive impairment, and motor symptoms including dyskinesias. In contrast, tremor was unrelated to amantadine use."

Observational data • Parkinson's Disease

Oral Caffeine vs Amantadine for Neurostimulation in Traumatic Brain Injury and Acute Ischemic Stroke (SCCM 2026) - "These results suggest that caffeine and amantadine have similar efficacy for neurostimulation in AIS and TBI. Amantadine may be associated with tachycardia and agitation, while caffeine may be associated with tachycardia and cardiac arrhythmias. Due to the single-center retrospective design of this trial, further studies need to be conducted to confirm these findings."

Cardiovascular • CNS Disorders • Cognitive Disorders • Ischemic stroke • Vascular Neurology

Toxicokinetics and postmortem redistribution of amantadine in rats. (PubMed, Front Med (Lausanne)) - "The findings underscore the limitations of relying solely on postmortem blood concentrations and support the complementary use of selected tissues and inter-tissue concentration ratios as comparative indicators in toxicological interpretation. These results offer mechanistic insight into postmortem drug dynamics and provide practical reference data to improve the interpretation of suspected amantadine intoxication."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Delayed-onset Parkinsonism Following BCMA-directed CAR-T Therapy (AAN 2026) - "He received high-dose dexamethasone with a prednisone taper. He showed poor response to sequential monotherapies, including carbidopa/levodopa, carbidopa/levodopa plus entacapone, ropinirole and rotigotine. Combination therapy with rotigotine, amantadine, and levodopa induced hallucinations. Midodrine improved orthostasis, but overall pharmacological response was minimal... This case underscores MNT as a significant delayed complication of BCMA-directed CAR-T therapy, aligning with European Society for Blood and Marrow Transplantation (EBMT) guidelines. It emphasizes the need for extended neurological surveillance, recognition of limited dopaminergic therapy efficacy, early immunomodulatory interventions despite inconsistent results and involvement in registries to better elucidate prevalence, underlying mechanisms, and optimal management strategies."

IO biomarker • CNS Disorders • Depression • Gastrointestinal Disorder • Hematological Malignancies • Hypotension • Infectious Disease • Inflammation • Movement Disorders • Multiple Myeloma • Parkinson's Disease • Septic Shock

Which Medication Improves Fatigue in Patients With Multiple Sclerosis (MS)?: A Systematic Review and Network Meta-analysis (AAN 2026) - "Objective: we designed this systematic review and network meta-analysis to compare the efficacy of Amantadine, Adderall, modafinil, and methylphenidate in treating MS-related fatigue, and improving processing speed in patients with MS.Background: Fatigue is a disabling symptom of multiple sclerosis (MS) with an unknown etiology. Among the prescribed medications for managing MS-related fatigue, only amantadine was found to be superior to placebo in improving the impact of fatigue on patients' lives."

Retrospective data • Review • CNS Disorders • Fatigue • Multiple Sclerosis

Optimal Amantadine Dosing Strategy for Neurological and Functional Recovery in Traumatic Brain Injury: A Network-metanalysis (AAN 2026) - "Amantadine, especially 200 mg daily, improves early neurological and functional outcomes in TBI, while 100 mg BID may enhance cognition. Moderate dosing appears most effective, supporting further trials to optimize regimens."

CNS Disorders • Vascular Neurology

A Novel Therapeutic Use of Amantadine for Palilalia and Bruxism Following Anoxic Brain Injury (AAN 2026) - " A 63-year-old woman was found unresponsive at home with respiratory depression and severe hypoxemia near a prescription bottle of alprazolam used for anxiety. This case supports a possible role for amantadine in post-anoxic encephalopathy presenting with palilalia and bruxism. Amantadine may enhance dopaminergic signaling and attenuate glutamatergic activity, potentially stabilizing basal ganglia–thalamocortical and frontal–subcortical circuits implicated in speech initiation and oromotor control. Reports of improvement in palilalia or bruxism after anoxia are rare; post-anoxic bruxism has been treated with botulinum toxin in case reports, and palilalia after anoxic injury is described but uncommon."

CNS Disorders • Dental Disorders • Depression • Epilepsy • Infectious Disease • Vascular Neurology

Comparison of the Effects of Amantadine, Methylprednisolone and Nimodipine in Sciatic Nerve Crush Injury. (PubMed, Turk Neurosurg) - "Overall, amantadine had the most positive cellular effects after sciatic nerve injury, though further research is required to explore optimal dosage, frequency, administration route, and additional clinical parameters In this study, amantadine was found to have the most favorable effects on nerve regeneration, but other drugs showed limited effects on some parameters. However, the lack of superiority in combined applications and the lack of clarification of ideal treatment conditions suggest the need for more comprehensive research in the future."

Journal

Consensus Molecules Associated with Parkinson's Disease. (PubMed, Neurol Int) - "Drugs include L-dopa (49%), carbidopa (63%), benserazide (50%), entacapone (74%), tolcapone (56%), rasagiline (76%), selegiline (46%), pargyline (4%), ropinirole (61%), pramipexole (56%), lisuride (27%), cabergoline (16%), bromocriptine (12%), and zonisamide (9%). Adjunctive therapies include droxidopa (33%), trihexyphenidyl (28%), biperiden (17%), amantadine (24%), memantine (7%), rivastigmine (13%), donepezil (6%), galantamine (4%), domperidone (6%), clonazepam (4%), tetrabenazine (16%), mazindol (13%), quetiapine (6%), and clozapine (4%). Contraindicated drugs include haloperidol (4%), sulpiride (3%), and methyldopa (6%)...Chemical inducers of PD include 6-hydroxydopamine (40%), N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 78%), tetrahydropyridine (77%), probenecid (4%), quinolinic acid (4%), 1,2,3,4-tetrahydroisoquinoline (TIQ, 16%), salsolinol (32%), rotenone (25%), and β-Methylamino-L-alanine (BMAA, 29%). Notably, our study highlights conditional essential..."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Label-free fluorescence lateral flow biosensing platform based on host-guest recognition for on-site detection of amantadine in egg samples. (PubMed, Food Chem) - "As a result, it has successfully achieved sensitive detection of AMD with a low limit of detection (LOD = 2.1 ng mL-1), wide linear detection range (2.5-100 ng mL-1), high specificity (CR ≤ 4%) and fast response (only 8 min). It will be expected to provide a novel avenue for rapid on-site detection of more illegal drugs in practices."

Journal

Molecular markers of endogenous neuroprotection in the brain of rats with experimental Parkinson's disease treated with various pharmacotherapy regimens. (PubMed, Wiad Lek) - " We have experimentally demonstrated a new target of neuroprotection in PD conditions - apoptosis of dopamine-producing neurons and substantiated modulators of this process - drugs for combined therapy with amantadine (melatonin, cerebrocurin, pronoran, and gliatilin) as promising drugs for PD treatment."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease • HIF1A

Evaluation of neurotoxicity of drugs from morphological and electrophysiological endpoints using human iPSC-derived neural cell models. (PubMed, Front Cell Infect Microbiol) - "The research results showed that oxaliplatin and emodin at concentrations higher than 10 μg/mL, phenytoin sodium at concentrations exceeding 50 μg/mL, acrylamide and amantadine at concentrations exceeding 100 μg/mL, as well as aconitine and isoniazid (100 μg/mL) have a toxic effect on neurite outgrowth (p<0.05, p<0.01). This model enables a more comprehensive evaluation of neurotoxicity in neurotherapeutic drugs, nano-pharmaceuticals, and environmental organic compounds from the perspective of changes in neurite outgrowth and neural network functionality. The method has specific test endpoints and high sensitivity, and can achieve high-throughput drug screening, which is expected to be applied to the safety risk assessment and scientific supervision of drugs with potential neurotoxicity, especially various types of neurotherapeutic drugs."

Journal

Amantadine Attenuates Secondary Oxidative and Inflammatory Injury by Modulating the HIF-1α/BNIP3L/HMGB1 Axis in Rat Model of Traumatic Brain Injury. (PubMed, Medicina (Kaunas)) - " In this experimental model, amantadine ameliorated oxidative, inflammatory, and apoptotic markers and was associated with reduced expression of HIF-1α, BNIP3L, and HMGB1. These findings support a mechanistic correlation between ATD treatment and suppression of secondary injury signatures; however, causal pathway relationships and functional neurological outcomes were not assessed."

Journal • Preclinical • CNS Disorders • Inflammation • Metabolic Disorders • Vascular Neurology • BNIP3L • CASP3 • HIF1A • HMGB1 • TNFA

Development and Validation of a UPLC-MS/MS Method for the Quantification of Amantadine in Rat Plasma: Application to a Pharmacokinetic Study Under High-Altitude Hypoxia and Mechanistic Insights. (PubMed, Pharmaceuticals (Basel)) - "Background/Objectives: This study aimed to develop an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for quantifying amantadine (AMA) in rat plasma and to investigate its pharmacokinetics under simulated high-altitude hypoxia, contrasting its behavior with that of its structural analog memantine (MEM). This profile starkly differs from the heightened exposure and reduced clearance observed for drugs like MEM, which are predominantly cleared by hepatic metabolism (under the studied conditions). These findings are consistent with the concept that a drug's primary elimination pathway (renal excretion vs. hepatic metabolism) critically determines its pharmacokinetic susceptibility to hypoxic stress."

Journal • PK/PD data • Preclinical

Intensive Care Management and Outcomes of Neuroleptic Malignant Syndrome: A Single-Center Retrospective Study. (PubMed, Medicina (Kaunas)) - "Bromocriptine was administered in 54.8% of cases, dantrolene in 4.8%, and amantadine in 11.9%. Patients with neuroleptic malignant syndrome often present with a severe clinical course requiring advanced organ support in the intensive care unit. However, with early diagnosis and appropriate intensive care management, mortality can be maintained at acceptable levels."

Journal • Retrospective data • Acute Kidney Injury • Cardiovascular • CNS Disorders • Critical care • Nephrology • Renal Disease

A Case of Psychosis Caused by Long-Term Overdose of Compound Paracetamol and Amantadine Hydrochloride Capsules. (PubMed, Bipolar Disord) - No abstract available

Journal • CNS Disorders • Psychiatry

Zanamivir-Amantadine Conjugate: A Dual-Action Agent with Broad-Spectrum Synergistic Antiviral Efficacy. (PubMed, J Med Chem) - "Notably, a single intravenous dose of 7j fully protected mice from a lethal H1N1 challenge. Our work demonstrates that the rational fusion of ZMV and Aman achieves synergistic multimechanistic antiviral activity with enhanced efficacy and safety, offering a new strategy for the development of next-generation anti-influenza drugs."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Synchronous point-of-care visualization and sensitive detection of amantadine by pattern-assisted electrochromic-photoelectrochemical dual-mode sensor. (PubMed, Food Chem) - "It exhibits high selectivity, stability, and reproducibility, and is capable of sensitive detection in real chicken and beef samples. This work presents a strategy for qualitative naked-eye observation and quantitative detection, respectively, realizing rapid classification and sensitive determination of pharmaceutical residues in food of animal origin."

Journal